Abcentra Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Abcentra is a clinical-stage biopharmaceutical company focused on developing treatments for coronary artery disease with the goal of preventing heart attacks. Its lead product, Orticumab, targets oxidized LDL, aiming to reduce coronary inflammation and potentially improve safety and efficacy compared with other anti-inflammatory approaches for CAD. The company intends to repurpose and extend the use of Orticumab from secondary prevention after an acute coronary syndrome toward primary prevention in patients with coronary inflammation.

Based in Los Angeles, Abcentra operates within the biotechnology research sector and is advancing its therapies as antibody-based interventions for inflammatory aspects of cardiovascular disease. While its work is at the clinical-stage, the organization concentrates on delivering options for patients at risk of recurrent cardiac events, and has pursued collaborations to measure changes in coronary inflammation as part of evaluating therapeutic impact.

Get verified Abcentra emails free

Company overview Employee directory